Elaine J Heron bought stock once, on Feb 27, 2026
Director at Palvella Therapeutics, Inc., and 1 other company
SEC CIK 0001235471 · Filings on SEC.gov ↗
Elaine J Heron's record
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Companies
Every filing
3 filings since Dec 2017, newest first
About Elaine J Heron
Elaine J. Heron, Ph.D. is a seasoned life sciences executive serving as an independent Director at Palvella Therapeutics, Inc. (NASDAQ: PVLA), a clinical-stage biopharmaceutical company developing therapies for serious rare skin diseases.( Appointed to the Palvella board in 2018, she brings extensive expertise in rare diseases, commercial leadership, finance, and R&D, and recently purchased 2,400 shares for $300,000 on February 27, 2026, increasing her direct ownership to 47,812 shares.(
Dr. Heron holds a B.S. in chemistry (highest distinction), a Ph.D. in analytical biochemistry from Purdue University, and an MBA from Pepperdine University.( Her career highlights include serving as Chair and CEO of Amplyx Pharmaceuticals (acquired by Pfizer in 2021) from 2009 to 2015 and Labcyte Inc. from 2001 to 2008, as well as General Manager and VP of Sales/Marketing at Applied Biosystems.( She currently holds board positions at public companies like Vaxart (since 2022), BioMarin Pharmaceutical (since 2002), and others including Visgenx, BlueWhale Bio, and Zephyrus Biosciences.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.